Drug Profile
Lefitolimod - Mologen
Alternative Names: GS-1703; MGN-1703Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Mologen
- Developer Aarhus Universitetshospital; Mologen; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Antivirals; DNA; Immunotherapies
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Colorectal cancer
- Phase II HIV-1 infections; Small cell lung cancer
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 02 Jun 2023 Adverse events data from a phase I trial in solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 01 May 2023 Aarhus University Hospital completes the phase IIa TITAN trial in HIV-1 infections (Combination therapy) in USA, Australia, Norway, Denmark (SC) (NCT03837756) (EudraCT2018-001165-16)
- 21 Feb 2023 Pharmacodynamics data from the phase IIa TITAN trial in HIV-1 infections presented at the Conference on Retroviruses and Opportunistic Infections (CROI-2023)